Literature DB >> 3516381

Autocrine tumor growth regulation and tumor-associated hypoglycemia in murine melanoma B16 in vivo.

S Vuk-Pavlović, E C Opara, S Levanat, D Vrbanec, K Pavelić.   

Abstract

A substance immunochemically cross-reactive with insulin (SICRI) appears in melanoma B16 growing in diabetic and nondiabetic C57BL/6 mice. Progression of tumor size is paralleled by the increase of SICRI levels in the serum of both diabetic and nondiabetic animals; this increase correlates with a decreased concentration of circulating glucose and an elevated concentration of growth hormone in blood. Melanoma B16 grown under serum-free culture conditions secretes SICRI into the medium. Affinity-purified SICRI stimulates glucose uptake by rat epididymal adipocytes and competes with radiolabeled insulin for binding to these cells. Low concentrations of SICRI enhance growth of cultured melanoma B16 cells, whereas high concentrations of this substance have inhibitory growth effects on these cells. Porcine insulin, human insulin-like growth factors I and II, human growth hormone, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor have negligible influence on growth of melanoma B16.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516381

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Malignant progression of B16 melanoma cells induced in vitro by growth factors produced by highly malignant cells.

Authors:  C W Stackpole; L Groszek; S S Kalbag
Journal:  Clin Exp Metastasis       Date:  1995-03       Impact factor: 5.150

2.  The role of insulin-related substance in Hodgkin's disease.

Authors:  T Cabrijan; S Levanat; B Pekić; J Pavelić; R Spaventi; H Frahm; V Zjacić-Rotkvić; V Goldoni; D Vrbanec; M Misjak
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Tumour-associated hypoglycaemia in a murine cachexia model.

Authors:  T M McDevitt; M J Tisdale
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.